

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **COMMON SPLENDOR INTERNATIONAL HEALTH INDUSTRY GROUP LIMITED**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 286)**

### **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR CHAIRMAN OF AUDIT COMMITTEE, MEMBER OF NOMINATION COMMITTEE AND MEMBER OF REMUNERATION COMMITTEE**

This announcement is made by Common Splendor International Health Industry Group Limited (“**Company**”) in accordance with Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”).

The board of directors (“**Board**”) of the Company announces that Mr. Wong Yiu Kit, Ernest (黃耀傑) (“**Mr. Wong**”) has been appointed as an independent non-executive director of the Company (“**INED**”), the chairman of the audit committee of the Company (“**Audit Committee**”), a member of each of the nomination committee of the Company (“**Nomination Committee**”) and the remuneration committee of the Company (“**Remuneration Committee**”) with effect from 20 September 2017.

Mr. Wong, aged 50, has over 25 years of experience in venture capital, corporate finance, business development and general management. Mr. Wong served as the president and group chief financial officer of KVB Kunlun Holdings Limited (“**KVB**”) since November 2011 and as the chief financial officer and the company secretary of KVB’s subsidiary, KVB Kunlun Financial Group Limited, the shares of which are listed on the Stock Exchange (Stock Code: 8077) since October 2014. Mr. Wong was the vice president of Vertex Management (HK), an international venture capital firm listed in Singapore between July 2000 and October 2002. Mr. Wong also served as an independent non-executive director of Renheng Enterprise Holdings Limited (Stock Code: 3628), HongDa Financial Holding Ltd (Stock Code: 1822), Legend Strategy International Holdings Group Company Limited (Stock Code: 1355), Progressive Path Group Holdings Limited (Stock Code: 1581), China Regenerative Medicine International Limited (Stock Code: 8158) since October 2011, July 2014, November 2016, November 2016 and February 2017, respectively, each of the shares of such companies are listed on the Stock Exchange. Mr. Wong also served several positions at Adamas Finance Asia Limited, a company

listed on the London Stock Exchange (LSE Stock Code: ADAM), including its executive director from May 2008 to February 2014, its chief financial officer from May 2008 to October 2011 and its non-executive director since February 2014.

Mr. Wong obtained a bachelor's degree in business administration from The University of Hong Kong in 1991, a master's degree of science in investment management from The Hong Kong University of Science and Technology in 1998 and a master's degree of science in electronic engineering from the Chinese University of Hong Kong in 2008.

Mr. Wong was admitted as a fellow member of the Association of Chartered Certified Accountants and the Hong Kong Institute of Certified Public Accountants in November 1999 and October 2002, respectively. He was admitted as a chartered financial analyst of the Institute of Chartered Financial Analysts in September 1998 and an associate member of the Institute of Chartered Accountants in England and Wales in January 2008. He is a current member of the Hong Kong Securities Institute. He is also acting as the president of the Hong Kong University Graduates Association, the deputy chairman of the HKU Convocation, the court member of The University of Hong Kong, a committee member of the Association of Chartered Certified Accountants Hong Kong and an executive director of the Hong Kong Society of Financial Analysts.

Save as disclosed above, Mr. Wong (i) does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company (as respectively defined in the Listing Rules); (ii) does not have and is not deemed to have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance; (iii) has not held any other directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iv) does not hold any other positions in the Company and its subsidiaries as at the date of this announcement. Mr. Wong has met the independent guidelines set out in Rule 3.13 of the Listing Rules.

There are no other matters or information relating to the appointment of Mr. Wong that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited or to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

Mr. Wong will hold office for an initial term of one year commencing on 20 September 2017, which will continue thereafter. During Mr. Wong's tenure, his appointment may be terminated by either party giving the other not less than one month's notice in writing. Mr. Wong will be entitled to an annual basic salary of HK\$150,000, and a discretionary bonus to be determined at the discretion of the Board and the Remuneration Committee.

Following the appointment of Mr. Wong as an INED, the chairman of the Audit Committee, a member of each of the Nomination Committee and Remuneration Committee with effect from 20 September 2017, the minimum number of independent non-executive Directors and members of the Audit Committee as required under Rule 3.10(1) and Rule 3.21 of the Listing Rules will be fulfilled by the Company.

The Board would like to extend its welcome to Mr. Wong for joining the Board.

By order of the Board  
**Common Splendor International Health  
Industry Group Limited**  
**Cheung Wai Kuen**  
*Chairman*

Hong Kong, 20 September 2017

*As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen, Mr. Cheng Hau Yan and Mr. Ye Jiong Xian as executive Directors; Mr. Lin Jiang and Mr. Hou Kaiwen as non-executive Directors; and Mr. Mai Yang Guang, Mr. Lam Chi Wing and Wong Yiu Kit, Ernest as independent non-executive Directors.*